Association between 5-HTR1A gene C-1019G polymorphism and antidepressant response in patients with major depressive disorder: A meta-analysis.

IF 3.9 4区医学 Q1 PSYCHIATRY

World Journal of Psychiatry Pub Date : 2024-10-19 DOI:10.5498/wjp.v14.i10.1573

Huai-Neng Wu, Shuang-Yue Zhu, Li-Na Zhang, Bian-Hong Shen, Lian-Lian Xu

{"title":"Association between 5-HTR1A gene C-1019G polymorphism and antidepressant response in patients with major depressive disorder: A meta-analysis.","authors":"Huai-Neng Wu, Shuang-Yue Zhu, Li-Na Zhang, Bian-Hong Shen, Lian-Lian Xu","doi":"10.5498/wjp.v14.i10.1573","DOIUrl":null,"url":null,"abstract":"Background: Major depressive disorder (MDD) is a substantial global health concern, and its treatment is complicated by the variability in individual response to antidepressants.Aim: To consolidate research and clarify the impact of genetic variation on MDD treatment outcomes.Methods: Adhering to Preferred Reporting Items for Systematic Reviews and Meta-Analyses guidelines, a systematic search across PubMed, EMBASE, Web of Science, and the Cochrane Library was conducted without date restrictions, utilizing key terms related to MDD, serotonin 1A receptor polymorphism (5-HTR1A), C-1019G polymorphism, and antidepressant response. Studies meeting inclusion criteria were thoroughly screened, and quality assessed using the Newcastle-Ottawa Scale. Statistical analyses, including χ 2 and I² values, were used to evaluate heterogeneity and fixed-effect or random-effect models were applied accordingly.Results: The initial search yielded 1216 articles, with 11 studies meeting criteria for inclusion. Analysis of various genetic models showed no significant association between the 5-HTR1A C-1019G polymorphism and antidepressant efficacy. The heterogeneity was low to moderate, and no publication bias was detected through funnel plot symmetry and Egger's and Begg's tests.Conclusion: This meta-analysis does not support a significant association between the 5-HTR1A C-1019G polymorphism and the efficacy of antidepressant treatment in MDD. The findings call for further research with larger cohorts to substantiate these results and enhance the understanding of antidepressant pharmacogenetics.","PeriodicalId":23896,"journal":{"name":"World Journal of Psychiatry","volume":null,"pages":null},"PeriodicalIF":3.9000,"publicationDate":"2024-10-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11514568/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"World Journal of Psychiatry","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.5498/wjp.v14.i10.1573","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"PSYCHIATRY","Score":null,"Total":0}

引用次数: 0

Abstract

Background: Major depressive disorder (MDD) is a substantial global health concern, and its treatment is complicated by the variability in individual response to antidepressants.

Aim: To consolidate research and clarify the impact of genetic variation on MDD treatment outcomes.

Methods: Adhering to Preferred Reporting Items for Systematic Reviews and Meta-Analyses guidelines, a systematic search across PubMed, EMBASE, Web of Science, and the Cochrane Library was conducted without date restrictions, utilizing key terms related to MDD, serotonin 1A receptor polymorphism (5-HTR1A), C-1019G polymorphism, and antidepressant response. Studies meeting inclusion criteria were thoroughly screened, and quality assessed using the Newcastle-Ottawa Scale. Statistical analyses, including χ ² and I² values, were used to evaluate heterogeneity and fixed-effect or random-effect models were applied accordingly.

Results: The initial search yielded 1216 articles, with 11 studies meeting criteria for inclusion. Analysis of various genetic models showed no significant association between the 5-HTR1A C-1019G polymorphism and antidepressant efficacy. The heterogeneity was low to moderate, and no publication bias was detected through funnel plot symmetry and Egger's and Begg's tests.

Conclusion: This meta-analysis does not support a significant association between the 5-HTR1A C-1019G polymorphism and the efficacy of antidepressant treatment in MDD. The findings call for further research with larger cohorts to substantiate these results and enhance the understanding of antidepressant pharmacogenetics.

查看原文本刊更多论文

重度抑郁症患者的 5-HTR1A 基因 C-1019G 多态性与抗抑郁药反应之间的关系：荟萃分析

背景：重度抑郁障碍（MDD）是全球关注的重大健康问题，其治疗因个体对抗抑郁药反应的差异而变得复杂。目的：整合研究并阐明基因变异对MDD治疗结果的影响：根据《系统综述和元分析首选报告项目》（Preferred Reporting Items for Systematic Reviews and Meta-Analyses）指南，利用与 MDD、5-羟色胺 1A 受体多态性 (5-HTR1A)、C-1019G 多态性和抗抑郁药反应相关的关键术语，在 PubMed、EMBASE、Web of Science 和 Cochrane 图书馆进行了系统检索，没有日期限制。对符合纳入标准的研究进行了全面筛选，并使用纽卡斯尔-渥太华量表对研究质量进行了评估。统计分析（包括 χ 2 和 I² 值）用于评估异质性，并相应采用固定效应或随机效应模型：初步检索共获得 1216 篇文章，其中 11 项研究符合纳入标准。对各种遗传模型的分析表明，5-HTR1A C-1019G 多态性与抗抑郁药效之间没有显著关联。异质性为低度至中度，通过漏斗图对称性以及Egger和Begg检验未发现发表偏倚：这项荟萃分析不支持 5-HTR1A C-1019G 多态性与 MDD 抗抑郁剂疗效之间存在显著关联。这些研究结果要求对更大规模的队列进行进一步研究，以证实这些结果并加深对抗抑郁药物遗传学的理解。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

World Journal of Psychiatry PSYCHIATRY-

自引率

6.50%

发文量

110

期刊介绍： The World Journal of Psychiatry (WJP) is a high-quality, peer reviewed, open-access journal. The primary task of WJP is to rapidly publish high-quality original articles, reviews, editorials, and case reports in the field of psychiatry. In order to promote productive academic communication, the peer review process for the WJP is transparent; to this end, all published manuscripts are accompanied by the anonymized reviewers’ comments as well as the authors’ responses. The primary aims of the WJP are to improve diagnostic, therapeutic and preventive modalities and the skills of clinicians and to guide clinical practice in psychiatry.